Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-05724-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Zhengqin Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Aerospace Center Hospital, Haidian District, Beijing, 100049, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Graft vs Host Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Rabbit anti-human T lymphocyte globulin (ATLG) and anti-thymocyte globulin (ATG) are commonly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT). Yet, their efficacy and safety have seldom been compared in hematological malignancies with haploidentical HSCT. A retrospective analysis with 28 ATLG (total dosage, 20-30 mg/kg) and 18 ATG (total dosage, 8-10 mg/kg) patients were performed. The cumulative incidences of chronic GVHD and relapse were comparable between both groups. ATLG showed a trend towards a lower acute GVHD incidence (28.6% vs. 44.4%, P = 0.242) and 3-year non-relapse mortality (10.7% vs. 27.8%, P = 0.160), and had a significantly higher 3-year overall survival (OS, 64.3% vs. 33.3%, P = 0.033) and GVHD-free and relapse-free survival (GRFS, 32.1% vs. 11.1%, P = 0.045) compared with ATG. Multivariate Cox regression analysis demonstrated ATLG was independently associated with a favorable OS (hazard ratio [HR] = 0.37, 95% confidence interval [CI]: 0.16-0.86, P = 0.020) and GRFS (HR = 0.51, 95%CI: 0.26-1.00, P = 0.051). Furthermore, ATLG had a lower risk of fever (25.0% vs. 61.1%, P = 0.014) and hemorrhage cystitis (7.1% vs. 38.9%, P = 0.008) than ATG-T. In conclusion, ATLG confers more survival benefit and a better safety profile than ATG and can be used in hematological malignancies with haploidentical HSCT. Prospective designed trials with a larger sample size are warranted to confirm the results in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Aerospace Center Hospital, Haidian District, Beijing, 100049, China.
- Department of Hematology, Aerospace Center Hospital, Haidian District, Beijing, 100049, China. luorongmu@163.com.
- Department of Hematology, China Aerospace Science & Industry Corporation 731 Hospital, Fengtai District, Beijing, 100074, China. luorongmu@163.com.
- Department of Hematology, Aerospace Center Hospital, Haidian District, Beijing, 100049, China. wangjingbo721@126.com.
Zitieren
APA
Tian, Z., Man, Q., Yang, Y., Guan, H., Wang, Y., Luo, R., & Wang, J. (2024). Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation. Annals of Hematology. https://doi.org/10.1007/s00277-024-05724-w
Vancouver
Tian Z, Man Q, Yang Y, Guan H, Wang Y, Luo R, et al. Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation. Annals of Hematology. 2024. doi:10.1007/s00277-024-05724-w
BibTeX
@article{Tian2024,
author = {Tian, Zhengqin and Man, Qihang and Yang, Yixin and Guan, Hexian and Wang, Ying and Luo, Rongmu and Wang, Jingbo},
title = {Comparison of rabbit ATLG and ATG for GVHD prophylaxis in hematological malignancies with haploidentical hematopoietic stem cell transplantation},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-05724-w}
}
EUVIMED